Inhalational Anthrax — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for inhalational anthrax. 1 active patents protecting 1 drugs from 1+ originators. First major cliff: 2027. Daily refresh.

1
Approved drugs
1
Active US patents
80/100
Avg vulnerability
—
Annual revenue covered

Originators in Inhalational Anthrax

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Generic (originally Pfizer) 1 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating inhalational anthrax. Each bar = one year. Y-axis scaled to peak year (1 patents).

1
27

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Vibramycin
doxycycline
 Generic (originally Pfizer) 1 80 — 2027-12-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
7749532 Vibramycin method of use 80 2027-12-19

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
7749532 Vibramycin method of use 80 2027-12-19

Related